Viking Therapeutics (VKTX) Research & Development (2014 - 2026)
Viking Therapeutics' (VKTX) quarterly Research & Development came in at $115.8 million in Q2 2026, up 92.43% year-over-year from $60.2 million in Q2 2025, and down 22.91% quarter-over-quarter from $150.2 million in Q1 2026.
Powered by 
Analysis
Viking Therapeutics (VKTX) Research & Development (2014 - 2026) Analysis & Trends
Viking Therapeutics has disclosed Research & Development across 13 years of filings, most recently posting $115.8 million for Q2 2026.
- In Q2 2026, Research & Development rose 92.43% year-over-year to $115.8 million; the TTM figure through Jun 2026 stood at $509.3 million (up 227.92% YoY), while the FY2025 annual figure was $345.0 million, up 239.38% from the prior year.
- Research & Development came in at $115.8 million for Q2 2026 at Viking Therapeutics, down from $150.2 million in the prior quarter.
- In the past five years, Research & Development ranged from a high of $153.5 million in Q4 2025 to a low of $11.0 million in Q1 2023.
- Average Research & Development over 5 years is $46.1 million, with a median of $23.3 million recorded in 2024.
- Year-over-year, Research & Development dropped 12.32% in 2023 and surged 395.24% in 2025.
- Over 5 years, Research & Development stood at $16.2 million in 2022, then grew by 26.73% to $20.5 million in 2023, then soared by 51.14% to $31.0 million in 2024, then surged by 395.24% to $153.5 million in 2025, then fell by 24.57% to $115.8 million in 2026.
- Per Business Quant data, the three most recent Research & Development figures were $115.8 million in Q2 2026, $150.2 million in Q1 2026, and $153.5 million in Q4 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | R&D (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 649.01 Bn | 628.25 Bn | 17.26 Bn | 3.65 Bn |
| 2 | AbbVie | 468.55 Bn | 462.03 Bn | 12.70 Bn | 2.34 Bn |
| 3 | Merck | 365.49 Bn | 358.40 Bn | 12.21 Bn | 9.74 Bn |
| 4 | Novartis Ag | 272.39 Bn | 265.10 Bn | 11.24 Bn | -2.85 Bn |
| 5 | Astrazeneca | 253.18 Bn | 247.96 Bn | 12.86 Bn | -4.05 Bn |
| 6 | Amgen | 219.53 Bn | 205.54 Bn | 7.24 Bn | 1.87 Bn |
| 7 | Gilead Sciences | 187.85 Bn | 184.59 Bn | 6.22 Bn | 1.76 Bn |
| 8 | Pfizer | 160.56 Bn | 149.16 Bn | 10.94 Bn | 2.81 Bn |
| 9 | Vertex Pharmaceuticals | 130.81 Bn | 122.96 Bn | 2.84 Bn | 993.80 Mn |
| 10 | Viking Therapeutics | 4.86 Bn | 4.86 Bn | - | 115.75 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 115.75 Mn |
| Mar 31, 2026 | 150.15 Mn |
| Dec 31, 2025 | 153.46 Mn |
| Sep 30, 2025 | 89.95 Mn |
| Jun 30, 2025 | 60.15 Mn |
| Mar 31, 2025 | 41.39 Mn |
| Dec 31, 2024 | 30.99 Mn |
| Sep 30, 2024 | 22.79 Mn |
| Jun 30, 2024 | 23.77 Mn |
| Mar 31, 2024 | 24.10 Mn |
| Dec 31, 2023 | 20.50 Mn |
| Sep 30, 2023 | 18.38 Mn |
| Jun 30, 2023 | 13.92 Mn |
| Mar 31, 2023 | 11.01 Mn |
| Dec 31, 2022 | 16.18 Mn |
| Sep 30, 2022 | 11.96 Mn |
| Jun 30, 2022 | 13.54 Mn |
| Mar 31, 2022 | 12.56 Mn |
| Dec 31, 2021 | 9.85 Mn |
| Sep 30, 2021 | 10.80 Mn |
API Access
Viking Therapeutics Research & Development API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=research-and-development&ticker=VKTX&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "research-and-development", "ticker": "VKTX", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=research-and-development&ticker=VKTX&period=max&api_key=YOUR_API_KEY");
const data = await res.json();